JY
JSPR icon

Jeff Yass’s Jasper Therapeutics JSPR Stock Holding History

Jeff Yass’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,149
Closed -$8.35K – 13982
2026
Q1 		$9.77K Sell
11,149
-93,638
-89% -$130K ﹤0.01% 12942
2025
Q4 		$192K Buy
104,787
+69,195
+194% +$139K ﹤0.01% 10920
2025
Q3 		$84.7K Sell
35,592
-25,294
-42% -$76.7K ﹤0.01% 11657
2025
Q2 		$338K Buy
60,886
+44,795
+278% +$221K ﹤0.01% 10073
2025
Q1 		$69.2K Sell
16,091
-6,723
-29% -$44.7K ﹤0.01% 11745
2024
Q4 		$488K Buy
22,814
+2,294
+11% +$47.8K ﹤0.01% 8723
2024
Q3 		$386K Buy
+20,520
New +$409K ﹤0.01% 9069
2024
Q2 		– Sell
-8,084
Closed -$194K – 12671
2024
Q1 		$237K Buy
+8,084
New +$144K ﹤0.01% 10230
2023
Q2 		– Sell
-1,382
Closed -$20.5K – 12641
2023
Q1 		$25K Sell
1,382
-2,055
-60% -$38K ﹤0.01% 11978
2022
Q4 		$16.3K Buy
+3,437
New +$23K ﹤0.01% 11830

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's JSPR Position: Q2 2026 in Review

Jeff Yass sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 11,149 shares — an estimated $8.35K sold.

Jeff Yass first reported a position in JSPR in Q4 2022 and held it in 10 quarters. The position peaked at $488K in Q4 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Jeff Yass reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 11,149 Jasper Therapeutics shares in Q2 2026, an estimated $8.35K.
  • Jeff Yass first reported a position in Jasper Therapeutics in Q4 2022 and held it in 10 quarters.
  • Jeff Yass's Jasper Therapeutics position peaked at $488K in Q4 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.